Scarica l'app Stockscreener
67.96
0.31%
-0.21
Dopo l'orario di chiusura:
67.96
Precedente Chiudi:
$68.17
Aprire:
$68.16
Volume 24 ore:
296.37K
Relative Volume:
0.49
Capitalizzazione di mercato:
$2.89B
Reddito:
$451.36M
Utile/perdita netta:
$-66.42M
Rapporto P/E:
-42.22
EPS:
-1.6097
Flusso di cassa netto:
$-22.31M
1 W Prestazione:
-7.23%
1M Prestazione:
+11.81%
6M Prestazione:
+37.68%
1 anno Prestazione:
+46.24%
Intervallo 1D:
$67.50
$69.09
Intervallo di 1 settimana:
$67.43
$75.20
Portata 52W:
$38.51
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Nome
Tarsus Pharmaceuticals Inc
Settore
Industria
Telefono
(949) 409-9820
Indirizzo
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
67.96 | 2.89B | 451.36M | -66.42M | -22.31M | -1.6097 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-27 | Ripresa | H.C. Wainwright | Buy |
| 2023-11-20 | Iniziato | Goldman | Neutral |
| 2023-07-18 | Iniziato | William Blair | Outperform |
| 2023-05-18 | Iniziato | Guggenheim | Buy |
| 2022-08-01 | Iniziato | Barclays | Overweight |
| 2021-12-21 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-23 | Iniziato | Oppenheimer | Outperform |
| 2020-11-10 | Iniziato | BofA Securities | Buy |
| 2020-11-10 | Iniziato | Jefferies | Buy |
| 2020-11-10 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-11-10 | Iniziato | Raymond James | Strong Buy |
Mostra tutto
Tarsus Pharmaceuticals Inc Borsa (TARS) Ultime notizie
Tarsus Pharmaceuticals at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Down 6.1%Should You Sell? - MarketBeat
Quantbot Technologies LP Reduces Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
(TARS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Jefferies Financial Group Inc. - MarketBeat
The Bull Case For Tarsus Pharmaceuticals (TARS) Could Change Following First 2026 XDEMVY Sales Outlook - Sahm
Tarsus Pharmaceuticals Bets Big on XDEMVY Growth - TipRanks
Tarsus (TARS) CHRO granted 27,310 options and 17,161 RSUs - Stock Titan
Tarsus (TARS) CEO Bobak Azamian granted stock options and RSUs with multi-year vesting - Stock Titan
Total debt per share of Tarsus Pharmaceuticals, Inc. – BX:TARS - TradingView
Tarsus Reports Soaring Xdemvy Sales in Q4, Full Year - Orange County Business Journal
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Mixed Share Performance - Yahoo Finance
Citigroup Inc. Increases Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
XDEMVY Growth And China Deal Reshape Tarsus Pharmaceuticals Investment Story - Sahm
What dividend safety score for Tarsus Pharmaceuticals Inc. stockDividend Hike & AI Powered Market Trend Analysis - Naître et grandir
Aug Gainers: Why is Tarsus Pharmaceuticals Inc stock going downPortfolio Update Summary & Stock Timing and Entry Methods - baoquankhu1.vn
FOMO Trade: Will Tarsus Pharmaceuticals Inc benefit from rising consumer demand2025 Performance Recap & Low Risk Growth Stock Ideas - baoquankhu1.vn
Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating - Yahoo Finance
Tarsus Pharma COO Neervannan Seshadri sells $641k in stock By Investing.com - Investing.com Australia
Tarsus Pharma COO Neervannan Seshadri sells $641k in stock - Investing.com India
10 Fastest Growing NASDAQ Stocks to Buy - Insider Monkey
[144] Tarsus Pharmaceuticals, Inc. SEC Filing - Stock Titan
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Vanguard Group Inc. - MarketBeat
Tarsus Pharmaceuticals at TD Cowen Conference: Eyeing Blockbuster Growth By Investing.com - Investing.com Canada
TARS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
A Look At Tarsus Pharmaceuticals (TARS) Valuation After 2025 Results And New Shelf Registration - Sahm
Tarsus Pharmaceuticals (TARS) Stock Analysis: Strong Buy Ratings and 21.88% Upside Potential - DirectorsTalk Interviews
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen - ChartMill
Aug PreEarnings: Why is Oak Woods Acquisition Corporation Equity Right stock going upWeekly Trade Recap & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Artisan Partners Limited Partnership Boosts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
(TARS) Risk Channels and Responsive Allocation - Stock Traders Daily
Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to Hold Rating by Zacks Research - MarketBeat
Tarsus to Participate in Upcoming Investor Conferences - Bitget
HC Wainwright Brokers Decrease Earnings Estimates for TARS - MarketBeat
Tarsus Pharmaceuticals (TARS) Is Up 14.8% After XDEMVY-Fueled Revenue Surge and New Equity Shelf Filing - simplywall.st
Stream Tarsus Pharma at TD Cowen and Barclays investor events in March - Stock Titan
Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines? - Yahoo Finance
Tarsus Pharmaceuticals (TARS) Receives Analyst Rating Upgrade fr - GuruFocus
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $105.00 Price Target at Oppenheimer - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $90.00 at Guggenheim - MarketBeat
TARS: Guggenheim Raises Price Target to $90, Maintains Buy Ratin - GuruFocus
Oppenheimer Adjusts Price Target on Tarsus Pharmaceuticals to $105 From $95, Maintains Outperform Rating - marketscreener.com
Analysts Offer Predictions for TARS FY2030 Earnings - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Healthcare Innovator with 32.92% Potential Upside - DirectorsTalk Interviews
Tarsus Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - VisionMonday.com
Tarsus Pharmaceuticals (TARS) Narrowing EPS Loss Backs Bullish Earnings Turnaround Narrative - simplywall.st
Tarsus Pharmaceuticals: Q4 Results Highlight Xdemvy Blockbuster Potential (NASDAQ:TARS) - Seeking Alpha
Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap UpTime to Buy? - MarketBeat
Tarsus Pharmaceuticals (TARS) Shares Surge Over 11% - GuruFocus
Tarsus Pharmaceuticals Inc Azioni (TARS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):